Combination chemotherapy with irinotecan and cisplatin as second-line treatment for small cell lung cancer |
| |
Authors: | Jie Luo Ying Xu Songwen Zhou Aiwu Li Di Zheng Jianfang Xu Caicun Zhou |
| |
Affiliation: | Department of Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200433, China |
| |
Abstract: | Objective: To evaluate the efficacy and safety of irinotecan (CPT-11) plus cisplatin (DDP) in patients with small call lung cancer (SCLC) as second-line chemotherapy.Methods: Patients received irinotecan 60 mg/m2 on days 1, 8, 15,and cisplatin 25 mg/m2 on days 1-3, every 28 days one cycle.Response was evaluated every two cycles and patients were follow-up for two years or until death.Results: Among the 28 evaluable patients, there were 1 CR, 7 PR, 8 SD and 12 PD.The response rate was 28.6% (8/28).Median time to progression (TTP) was 3.2 (0.8-5.6) months.Median survival aftersecond-line treatment was 7.5 (1.5-31) months and overall survival was 15 (2.3-43.5) months.The most common adverseeffect was hematological toxicity with 36.7% (11/30), grades Ⅲ-Ⅳ neutroperia.Hepatic toxicity was another major side effect.Only one patient developed grade Ⅲ diarrhea.Conclusion: The combination of irinotecan and cisplatin is feasible, effective,and safe for SCLC as second-line treatment. |
| |
Keywords: | lung neoplasms small cell lung cancer irinotecan second-line treatment |
本文献已被 维普 万方数据 SpringerLink 等数据库收录! |
|